<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236755</url>
  </required_header>
  <id_info>
    <org_study_id>H-ZG50-2</org_study_id>
    <nct_id>NCT01236755</nct_id>
  </id_info>
  <brief_title>Discontinuation of Lens Wear in New Ortho-k Children (DOEE2)</brief_title>
  <acronym>DOEE2</acronym>
  <official_title>Discontinuation of Orthokeratology on Eyeball Elongation (DOEE) Study. (2) Discontinuation of Lens Wear in New Ortho-k Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hong Kong Polytechnic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Menicon Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hong Kong Polytechnic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at investigating the efficacy of myopic control using ortho-k in younger and
      older children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children wearing ortho-k have been shown to have slower rate of myopic progression than those
      wearing single-vision spectacles (Cho et al. 2005) or soft lenses (Walline et al. 2009).
      Younger myopic children (aged 6-10 years old) may have the faster increase in myopia than old
      myopic children (aged 11-15 years old), i.e. the rate of myopic progression may be different
      in different age groups and in children with different refractive status (Edwards 1999; Fan
      et al. 2004; Cheng et al. 2007). Although the refractive correction with ortho-k has been
      well documented, it is unknown whether the efficiency and reversibility of ortho-k for myopic
      reduction as well as myopic control are similar in children of different age and refractive
      groups.

      In this 14-month study, the eyeball length in 45 younger (6-10 years old) and 45 older (11-15
      years old) myopic children before and after ortho-k will be evaluated. Eyeball elongation
      will be determined for the first 7 months when single-vision glasses will be prescribed
      (Phase I) and the next 7 months when ortho-k will be prescribed (Phase I). Rate of myopic
      progression will be determined and compared between the two groups of children in the two
      phases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects were prescribed with a pair of glasses for seven months and switched to orthokeratology for another seven months</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
    <masking_description>The outcome assessor was responsible for measuring the axial length and was unaware of the intervention (i.e. spectacles or orthokeratology) used by the subjects</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Axial Elongation in the Two Study Phases</measure>
    <time_frame>14 months</time_frame>
    <description>Axial elongation in children during the two study phases. Phase I: 7 months wearing single-vision spectacles. Phase II: 7 months wearing orthokeratology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Effects</measure>
    <time_frame>14 months</time_frame>
    <description>Number of subjects with serious adverse effects of the cornea, the palpebral, bulbar and tarsal conjunctiva</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>ortho-k lenses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children were switched to wear ortho-k lenses for 7 months after wearing single-vision glasses for 7 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>single-vision glasses</intervention_name>
    <description>Daily wear of glasses to correct vision in the first seven months of the study</description>
    <arm_group_label>ortho-k lenses</arm_group_label>
    <other_name>CR-39 lenses</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ortho-k lenses</intervention_name>
    <description>Nightly wear of lenses to correct vision in day time in the second seven months of the study</description>
    <arm_group_label>ortho-k lenses</arm_group_label>
    <other_name>orthokeratology</other_name>
    <other_name>corneal reshaping therapy</other_name>
    <other_name>Menicon Z Night lenses</other_name>
    <other_name>Menicon Z Night Toric lenses</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: between 6 to 15 years old

          -  Myopia: between 1.50D and 4.50D in at least one eye

          -  Spherical equivalent (SE): between -1.00D to -4.50D in both eyes

          -  Astigmatism: ≤ 3.00D of axes 180 +/- 30 or ≤ 1.00D of other axes; and the amount is
             less than refractive sphere

          -  Anisometropia: ≤ 1.50D in both refractive sphere, refractive cylinder and SE

          -  Best corrected monocular visual acuity: equal to or better than 0.10 in logMAR scale
             in both eyes

          -  Willingness to wear contact lenses or spectacles on a daily basis

          -  Can obtain good ortho-k results with the study lenses

          -  Availability for follow-up for at least 14 months

        Exclusion Criteria:

          -  Strabismus at distance or near

          -  Contraindication for contact lens wear and ortho-k (e.g. limbus to limbus corneal
             cylinder and dislocated corneal apex

          -  Systemic or ocular conditions which may affect contact lens wear (e.g. allergy and
             medication)

          -  Systemic or ocular conditions which may affect refractive development (e.g. Down
             syndrome, ptosis)

          -  Prior experience with the use of rigid lenses (including ortho-k)

          -  Prior experience with myopia control treatment (e.g. refractive therapy or progressive
             spectacles)

          -  Non-compliance to the follow up schedule

          -  Non-compliance to the use of the prescribed optical correction

          -  Poor ocular response to ortho-k lens wear

          -  Significant residual refractive error after ortho-k treatment resulting in poor
             unaided vision (worse than 0.18 in logMAR scale)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline Cho, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hong Kong Polytechnic University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Optometry, The Hong Kong Polytechnic University</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cheng D, Schmid KL, Woo GC. Myopia prevalence in Chinese-Canadian children in an optometric practice. Optom Vis Sci. 2007 Jan;84(1):21-32.</citation>
    <PMID>17220775</PMID>
  </reference>
  <reference>
    <citation>Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res. 2005 Jan;30(1):71-80.</citation>
    <PMID>15875367</PMID>
  </reference>
  <reference>
    <citation>Edwards MH. The development of myopia in Hong Kong children between the ages of 7 and 12 years: a five-year longitudinal study. Ophthalmic Physiol Opt. 1999 Jul;19(4):286-94.</citation>
    <PMID>10645384</PMID>
  </reference>
  <reference>
    <citation>Fan DS, Lam DS, Lam RF, Lau JT, Chong KS, Cheung EY, Lai RY, Chew SJ. Prevalence, incidence, and progression of myopia of school children in Hong Kong. Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1071-5.</citation>
    <PMID>15037570</PMID>
  </reference>
  <reference>
    <citation>Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. Br J Ophthalmol. 2009 Sep;93(9):1181-5. doi: 10.1136/bjo.2008.151365. Epub 2009 May 4.</citation>
    <PMID>19416935</PMID>
  </reference>
  <results_reference>
    <citation>Cheung SW, Boost MV, Cho P. Pre-treatment observation of axial elongation for evidence-based selection of children in Hong Kong for myopia control. Cont Lens Anterior Eye. 2019 Aug;42(4):392-398. doi: 10.1016/j.clae.2018.10.006. Epub 2018 Oct 24.</citation>
    <PMID>30366778</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <results_first_submitted>February 21, 2019</results_first_submitted>
  <results_first_submitted_qc>August 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2019</results_first_posted>
  <last_update_submitted>February 29, 2020</last_update_submitted>
  <last_update_submitted_qc>February 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hong Kong Polytechnic University</investigator_affiliation>
    <investigator_full_name>Pauline Cho</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>corneal reshaping</keyword>
  <keyword>myopia</keyword>
  <keyword>myopia progression</keyword>
  <keyword>orthokeratology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects in Spectacle and Ortho-k Wearing Phases</title>
          <description>Subjects enrolled in the study during the first 7 months in Phase I (daily wear of single-vision spectacles) and the next 7 months in Phase II (nightly wear of orthokeratology lenses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Spectacles Wearing Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Orthokeratology Wearing Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Refractive Correction / Centration</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects Completed the 14-month Study</title>
          <description>Subjects who have completed the study in which they used single-vision spectacles every day for 7 months in Phase I and ortho-k lenses every night for the next 7 months in Phase II to correct their vision.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Axial Elongation in the Two Study Phases</title>
        <description>Axial elongation in children during the two study phases. Phase I: 7 months wearing single-vision spectacles. Phase II: 7 months wearing orthokeratology</description>
        <time_frame>14 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Axial Elongation in Spectacle and Ortho-k Wearing Phases</title>
            <description>Axial elongation in children during the first 7 months in Phase I (daily wear of single-vision spectacles) and the next 7 months in Phase II (nightly wear of orthokeratology lenses)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Axial Elongation in the Two Study Phases</title>
          <description>Axial elongation in children during the two study phases. Phase I: 7 months wearing single-vision spectacles. Phase II: 7 months wearing orthokeratology</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>spectacles wearing phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.163" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>orthokeratology wearing phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Effects</title>
        <description>Number of subjects with serious adverse effects of the cornea, the palpebral, bulbar and tarsal conjunctiva</description>
        <time_frame>14 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serious Adverse Events in Spectacle and Ortho-k Wearing Phases</title>
            <description>Number of subjects with serious adverse events in the cornea and conjunctiva during the first 7 months in Phase I (daily wear of single-vision spectacles) and the next 7 months in Phase II (nightly wear of orthokeratology lenses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Effects</title>
          <description>Number of subjects with serious adverse effects of the cornea, the palpebral, bulbar and tarsal conjunctiva</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>spectacles wearing phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>orthokeratology wearing phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study started in October 2010 and ended in July 2013. Adverse events during the 33 months were collected and reported</time_frame>
      <desc>It was a cross-over study in which there was only one Arm/Group. Therefore, the adverse events for the single-vision and orthokeratology phases were combined. The adverse events for each intervention can be found under the second primary outcome in which the results from the two interventions were presented in the two rows</desc>
      <group_list>
        <group group_id="E1">
          <title>Serious Adverse Events in Spectacle and Ortho-k Wearing Phase</title>
          <description>Number of subjects with serious adverse events of the cornea and conjunctiva during the first 7 months in Phase I (daily wear of single-vision spectacles) and the next 7 months in Phase II (nightly wear of orthokeratology lenses)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Pauline Cho</name_or_title>
      <organization>The Hong Kong Polytechnic University</organization>
      <phone>+852 2766-6100</phone>
      <email>pauline.cho@polyu.edu.hk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

